
Sign up to save your podcasts
Or
In this week's episode we’ll learn more about how clonal hematopoiesis affects prognosis in patients with telomere biology disorders, consider recently uncovered molecular subtypes of extracutaneous juvenile xanthogranulomas, and discuss a clinical trial of the BCMA-CD3 bispecific antibody teclistamab in patients with relapsed/refractory multiple myeloma who have received previous BCMA-targeted therapy.
Featured Articles:
4.1
4848 ratings
In this week's episode we’ll learn more about how clonal hematopoiesis affects prognosis in patients with telomere biology disorders, consider recently uncovered molecular subtypes of extracutaneous juvenile xanthogranulomas, and discuss a clinical trial of the BCMA-CD3 bispecific antibody teclistamab in patients with relapsed/refractory multiple myeloma who have received previous BCMA-targeted therapy.
Featured Articles:
129 Listeners
71 Listeners
319 Listeners
26 Listeners
489 Listeners
273 Listeners
2 Listeners
186 Listeners
362 Listeners
3 Listeners
2 Listeners
29 Listeners
165 Listeners
48 Listeners
1 Listeners